Cargando…
尼洛替尼和达沙替尼作为二三线药物治疗慢性髓性白血病慢性期和加速期患者的疗效及影响因素分析
OBJECTIVE: To explore the efficacy and prognosis of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia (CML) in the chronic phase (CP) and accelerated phase (AP). METHODS: From January 2008 to November 2018, the data of CML patients who failed first-...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357953/ https://www.ncbi.nlm.nih.gov/pubmed/32135623 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.02.002 |
_version_ | 1783558769334026240 |
---|---|
collection | PubMed |
description | OBJECTIVE: To explore the efficacy and prognosis of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia (CML) in the chronic phase (CP) and accelerated phase (AP). METHODS: From January 2008 to November 2018, the data of CML patients who failed first- or second-line tyrosine kinase inhibitor (TKI) -therapy received nilotinib or dasatinib as second-line and third-line therapy were retrospectively reviewed. RESULTS: A total of 226 patients receiving nilotinib or dastinib as second-line (n=183) and third-line (n=43) therapy were included in this study. With a median follow-up of 21 (range, 1–135) months, the cumulative rates of complete hematological response (CHR), complete cytogenetic response (CCyR) and major molecular response (MMR) were 80.4%, 56.3%and 38.3%, respectively in those receiving TKI as second-line TKI therapy. The 3-year progression-free survival (PFS) and overall survival (OS) rates were 78.7%and 93.1%, respectively. Multivariate analyses showed that Sokal high risk, female gender, the best response achieved <CHR on the first-line TKI-therapy, the interval from diagnosis to switching to second-line TKI ≥18 months, AP or hematologic failure, or non-specific mutation of BCR-ABL kinase domain before second-line TKI therapy, developing severe hematologic toxicity during the second-line TKI therapy were variables associated with poor responses or outcomes on second-line TKI therapy. With a median follow-up of 6 (range, 3–129) months, the cumulative CHR, CCyR and MMR were 95.7%, 29.3%, and 18.6%, respectively in those receiving the third-line TKI therapy. The 2-year PFS and OS rates were 66.8% and 93.8%, respectively. The patients with an interval from diagnosis to starting TKI ≥6 months, achieving no cytogenetic response on the second-line TKI, the interval from diagnosis to starting second-line TKI ≥60 months, and progression to AP before the third-line TKI therapy had lower probabilities of responses and unfavorable outcomes. CONCLUSIONS: The efficacy of dasatinib and nilotinib as second- or third-line TKI-therapy were active in the CML patients with TKI-resistance. The best response achieved on previous TKI-therapy, the disease phase before switching TKI, and the severe hematologic toxicity developing on the current TKI-therapy were associated with the responses and outcomes. |
format | Online Article Text |
id | pubmed-7357953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73579532020-07-16 尼洛替尼和达沙替尼作为二三线药物治疗慢性髓性白血病慢性期和加速期患者的疗效及影响因素分析 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To explore the efficacy and prognosis of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia (CML) in the chronic phase (CP) and accelerated phase (AP). METHODS: From January 2008 to November 2018, the data of CML patients who failed first- or second-line tyrosine kinase inhibitor (TKI) -therapy received nilotinib or dasatinib as second-line and third-line therapy were retrospectively reviewed. RESULTS: A total of 226 patients receiving nilotinib or dastinib as second-line (n=183) and third-line (n=43) therapy were included in this study. With a median follow-up of 21 (range, 1–135) months, the cumulative rates of complete hematological response (CHR), complete cytogenetic response (CCyR) and major molecular response (MMR) were 80.4%, 56.3%and 38.3%, respectively in those receiving TKI as second-line TKI therapy. The 3-year progression-free survival (PFS) and overall survival (OS) rates were 78.7%and 93.1%, respectively. Multivariate analyses showed that Sokal high risk, female gender, the best response achieved <CHR on the first-line TKI-therapy, the interval from diagnosis to switching to second-line TKI ≥18 months, AP or hematologic failure, or non-specific mutation of BCR-ABL kinase domain before second-line TKI therapy, developing severe hematologic toxicity during the second-line TKI therapy were variables associated with poor responses or outcomes on second-line TKI therapy. With a median follow-up of 6 (range, 3–129) months, the cumulative CHR, CCyR and MMR were 95.7%, 29.3%, and 18.6%, respectively in those receiving the third-line TKI therapy. The 2-year PFS and OS rates were 66.8% and 93.8%, respectively. The patients with an interval from diagnosis to starting TKI ≥6 months, achieving no cytogenetic response on the second-line TKI, the interval from diagnosis to starting second-line TKI ≥60 months, and progression to AP before the third-line TKI therapy had lower probabilities of responses and unfavorable outcomes. CONCLUSIONS: The efficacy of dasatinib and nilotinib as second- or third-line TKI-therapy were active in the CML patients with TKI-resistance. The best response achieved on previous TKI-therapy, the disease phase before switching TKI, and the severe hematologic toxicity developing on the current TKI-therapy were associated with the responses and outcomes. Editorial office of Chinese Journal of Hematology 2020-02 /pmc/articles/PMC7357953/ /pubmed/32135623 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.02.002 Text en 2020年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 论著 尼洛替尼和达沙替尼作为二三线药物治疗慢性髓性白血病慢性期和加速期患者的疗效及影响因素分析 |
title | 尼洛替尼和达沙替尼作为二三线药物治疗慢性髓性白血病慢性期和加速期患者的疗效及影响因素分析 |
title_full | 尼洛替尼和达沙替尼作为二三线药物治疗慢性髓性白血病慢性期和加速期患者的疗效及影响因素分析 |
title_fullStr | 尼洛替尼和达沙替尼作为二三线药物治疗慢性髓性白血病慢性期和加速期患者的疗效及影响因素分析 |
title_full_unstemmed | 尼洛替尼和达沙替尼作为二三线药物治疗慢性髓性白血病慢性期和加速期患者的疗效及影响因素分析 |
title_short | 尼洛替尼和达沙替尼作为二三线药物治疗慢性髓性白血病慢性期和加速期患者的疗效及影响因素分析 |
title_sort | 尼洛替尼和达沙替尼作为二三线药物治疗慢性髓性白血病慢性期和加速期患者的疗效及影响因素分析 |
topic | 论著 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357953/ https://www.ncbi.nlm.nih.gov/pubmed/32135623 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.02.002 |
work_keys_str_mv | AT níluòtìníhédáshātìnízuòwèièrsānxiànyàowùzhìliáomànxìngsuǐxìngbáixuèbìngmànxìngqīhéjiāsùqīhuànzhědeliáoxiàojíyǐngxiǎngyīnsùfēnxī AT níluòtìníhédáshātìnízuòwèièrsānxiànyàowùzhìliáomànxìngsuǐxìngbáixuèbìngmànxìngqīhéjiāsùqīhuànzhědeliáoxiàojíyǐngxiǎngyīnsùfēnxī AT níluòtìníhédáshātìnízuòwèièrsānxiànyàowùzhìliáomànxìngsuǐxìngbáixuèbìngmànxìngqīhéjiāsùqīhuànzhědeliáoxiàojíyǐngxiǎngyīnsùfēnxī AT níluòtìníhédáshātìnízuòwèièrsānxiànyàowùzhìliáomànxìngsuǐxìngbáixuèbìngmànxìngqīhéjiāsùqīhuànzhědeliáoxiàojíyǐngxiǎngyīnsùfēnxī AT níluòtìníhédáshātìnízuòwèièrsānxiànyàowùzhìliáomànxìngsuǐxìngbáixuèbìngmànxìngqīhéjiāsùqīhuànzhědeliáoxiàojíyǐngxiǎngyīnsùfēnxī AT níluòtìníhédáshātìnízuòwèièrsānxiànyàowùzhìliáomànxìngsuǐxìngbáixuèbìngmànxìngqīhéjiāsùqīhuànzhědeliáoxiàojíyǐngxiǎngyīnsùfēnxī AT níluòtìníhédáshātìnízuòwèièrsānxiànyàowùzhìliáomànxìngsuǐxìngbáixuèbìngmànxìngqīhéjiāsùqīhuànzhědeliáoxiàojíyǐngxiǎngyīnsùfēnxī |